Glaukos publishes investor presentation highlighting interventional glaucoma, keratoconus pipeline programs
GKOS•Pipeline programs and keratoconus focus
The presentation emphasized next-generation iDose devices: TRIO in Phase 3b and TREX in Phase 2b/3, targeting longer duration and broader use.
The keratoconus push featured Epioxa, described as a first FDA-cleared epithelium-on cross-linking therapy, commercially available since March 2026.
Investor presentation highlights interventional glaucoma strategy
Glaukos outlined a strategy centered on “interventional glaucoma” to reduce reliance on topical drops, citing high non-compliance rates.
- iDose TR is positioned as a long-duration travoprost implant designed to deliver up to 3 years; FDA re-administration clearance was noted for Jan. 2026.
- Clinical metrics highlighted included 81% of iDose TR subjects off IOP-lowering drops at 12 months and 70% well-controlled on the same or fewer medications at 3 years.
